Therapeutic Targeting of Myc

Overview

Journal Genes Cancer

Specialty Oncology

Date 2010 Dec 7

PMID 21132100

Citations 94

Authors

Edward V Prochownik

Peter K Vogt

Affiliations

Soon will be listed here.

Abstract

Protein-protein interactions between members of the Myc transcription factor network are potential targets of small molecule inhibitors and stabilizers. Diverse screening strategies, including fluorescence resonance energy transfer, fluorescence polarization, two hybrid and protein complementation assays have identified several lead compounds that inhibit Myc-Max dimerization and one compound that stabilizes the Max homodimer. Representative compounds interfere with Myc-induced transcriptional activation, Myc-mediated oncogenic transformation, Myc-driven cellular replication and DNA binding of Myc. For the best characterized compounds, specific binding sites have been determined, and molecular mechanisms of action have been documented. This knowledge of small molecule - protein interaction is currently applied to highly targeted approaches that seek to identify novel compounds with improved potency.

Citing Articles

New insights into protein-protein interaction modulators in drug discovery and therapeutic advance.

Nada H, Choi Y, Kim S, Jeong K, Meanwell N, Lee K Signal Transduct Target Ther. 2024; 9(1):341.

PMID: 39638817 PMC: 11621763. DOI: 10.1038/s41392-024-02036-3.

Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase.

Zhang J, Zhou S, Jiang S, He F, Tu Y, Hu H J Cancer Res Clin Oncol. 2024; 150(9):426.

PMID: 39299959 PMC: 11413099. DOI: 10.1007/s00432-024-05939-4.

Overcoming phenotypic switching: targeting protein-protein interactions in cancer.

Ladias C, Papakotoulas P, Papaioannou M, Papanikolaou N Explor Target Antitumor Ther. 2023; 4(5):1071-1081.

PMID: 38023990 PMC: 10651353. DOI: 10.37349/etat.2023.00181.

A Novel Transgenic Mouse Model Implicates as a Promoter of Hepatocellular Carcinoma.

Schmidt A, Monga S, Prochownik E, Goetzman E Int J Mol Sci. 2023; 24(16).

PMID: 37628798 PMC: 10454864. DOI: 10.3390/ijms241612618.

Lessons in aging from Myc knockout mouse models.

Prochownik E, Wang H Front Cell Dev Biol. 2023; 11:1244321.

PMID: 37621775 PMC: 10446843. DOI: 10.3389/fcell.2023.1244321.

References

Diaz-Gonzalez J, Russell J, Rouzaut A, Gil-Bazo I, Montuenga L . Targeting hypoxia and angiogenesis through HIF-1alpha inhibition. Cancer Biol Ther. 2005; 4(10):1055-62. DOI: 10.4161/cbt.4.10.2195. View

Smith M, Prochownik E . The leucine zipper of c-Myc is required for full inhibition of erythroleukemia differentiation. Mol Cell Biol. 1990; 10(10):5333-9. PMC: 361227. DOI: 10.1128/mcb.10.10.5333-5339.1990. View

Pulverer B, Fisher C, Vousden K, Littlewood T, Evan G, Woodgett J . Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene. 1994; 9(1):59-70. View

Mateyak M, Obaya A, Adachi S, Sedivy J . Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. 1997; 8(10):1039-48. View

Zhang F, Dong L, Ge J . Meta-analysis of five randomized clinical trials comparing sirolimus- versus paclitaxel-eluting stents in patients with diabetes mellitus. Am J Cardiol. 2010; 105(1):64-8. DOI: 10.1016/j.amjcard.2009.08.652. View

Farber S, DIAMOND L . Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948; 238(23):787-93. DOI: 10.1056/NEJM194806032382301. View

Jones S, Thornton J . Principles of protein-protein interactions. Proc Natl Acad Sci U S A. 1996; 93(1):13-20. PMC: 40170. DOI: 10.1073/pnas.93.1.13. View

Felsher D . Reversibility of oncogene-induced cancer. Curr Opin Genet Dev. 2004; 14(1):37-42. DOI: 10.1016/j.gde.2003.12.008. View

Kiessling A, Wiesinger R, Sperl B, Berg T . Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine. ChemMedChem. 2007; 2(5):627-30. DOI: 10.1002/cmdc.200600294. View

10.

Miyamoto-Sato E, Fujimori S, Ishizaka M, Hirai N, Masuoka K, Saito R . A comprehensive resource of interacting protein regions for refining human transcription factor networks. PLoS One. 2010; 5(2):e9289. PMC: 2827538. DOI: 10.1371/journal.pone.0009289. View

11.

Lu X, Vogt P, Boger D, Lunec J . Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. Oncol Rep. 2008; 19(3):825-30. View

12.

Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas M, Gudkov A . c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene. 2007; 27(13):1905-15. PMC: 3144565. DOI: 10.1038/sj.onc.1210823. View

13.

Boxer R, Jang J, Sintasath L, Chodosh L . Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell. 2004; 6(6):577-86. DOI: 10.1016/j.ccr.2004.10.013. View

14.

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

15.

Karlsson A, Giuriato S, Tang F, Levan G, Felsher D . Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood. 2003; 101(7):2797-803. DOI: 10.1182/blood-2002-10-3091. View

16.

Yin X, Grove L, Prochownik E . Lack of transcriptional repression by max homodimers. Oncogene. 1998; 16(20):2629-37. DOI: 10.1038/sj.onc.1201777. View

17.

Wrighton S, Schuetz E, Thummel K, Shen D, Korzekwa K, Watkins P . The human CYP3A subfamily: practical considerations. Drug Metab Rev. 2001; 32(3-4):339-61. DOI: 10.1081/dmr-100102338. View

18.

Nesbit C, Tersak J, Prochownik E . MYC oncogenes and human neoplastic disease. Oncogene. 1999; 18(19):3004-16. DOI: 10.1038/sj.onc.1202746. View

19.

Dhomen N, Marais R . BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am. 2009; 23(3):529-45, ix. DOI: 10.1016/j.hoc.2009.04.001. View

20.

Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M . Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002; 297(5578):102-4. DOI: 10.1126/science.1071489. View